Navidea Biopharmaceuticals has submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) for the approval to market and sale Lymphoseek Injection for sentinel lymph node (SLN) detection in patients ...
Navidea Biopharmaceuticals has launched its Lymphoseek (technetium Tc 99m tilmanocept) Injection in the US. The injection is used in lymphatic mapping procedures that help in the diagnostic evaluation of potential cancer spread for ...
Tags: Navidea, Lymphoseek
The US Food and Drug Administration (FDA) has approved Navidea Biopharmaceuticals' Lymphoseek (technetium Tc 99m tilmanocept) injection, a novel product indicated for use in lymphatic mapping procedure. The lymphatic mapping procedure ...
Tags: FDA, Biopharmaceuticals, Navidea Biopharma
Navidea Biopharmaceuticals has collaborated with Maimonides Medical Center to find the use of Lymphoseek (technetium Tc 99m tilmanocept) injection for lymphatic mapping in colorectal cancer. The investigator-initiated study will be ...
Tags: Navidea, Medical Center, medical market
Navidea Biopharmaceuticals has jouned forces with Maimonides Medical Centre to investigate Lymphoseek injections as a potential treatment for colorectal cancer. Dr. Danny Sherwinter, surgeon and the director of the Department of Minimally ...
Navidea Biopharmaceuticals has reported a net loss attributable to common stockholders of $9.12m, or $0.09 per share, for the third quarter ended 30 September 2012 compared to a net income attributable to common stockholders of $19.81m, or ...
Tags: Navidea Biopharmaceuticals, common stockholders, radiopharmaceutical